Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on January 31, 2025, the company granted equity awards to ...
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...
Le Lézard4d
AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia
AngioDynamics, Inc. , a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving ...
openheart.bmj4d
Complex high-risk indicated PCI (CHIP-PCI): is it safe to let fellows-in-training perform it as primary operators?
Background Training in complex high-risk indicated percutaneous coronary intervention (CHIP-PCI) has frequently been reserved for established operators (consultants ...